CYBERJAYA, MALAYSIA, July 17, 2025 - (ACN Newswire via SeaPRwire.com) - BlackBerry Limited (NYSE:BB)(TSX:BB) and EC-Council, a global leader in cybersecurity certifications and learning technology, today announced a new partnership that will offer government employees nationwide with increased access to cybersecurity training and certifications through the Cybersecurity Center of Excellence (CCoE) in Malaysia. The collaboration supports Malaysia's pioneering efforts to boost human cyber capital and strengthen the nation's defences against growing digital threats, equipping government employees with advanced, industry-relevant skills through flexible learning modules.In collaboration with the Malaysian Communications and Multimedia Commission (MCMC), the partnership will further expand the CCoE Cybersecurity Curriculum, which already offers a wide range of globally recognized course offerings and certifications. With the addition of the cutting-edge EC-Council Learning (ECL) platform, one of the world's most advanced cloud-based cybersecurity education ecosystems, the CCoE is expanding self-paced online and in-person learning for Malaysian civil servants, helping more men and women to upskill and complete courses in their own time.In support of the Malaysian government's commitment to cybersecurity capacity building, the addition of EC-Council Learning marks a significant evolution of the CCoE's curriculum, enhancing its existing programs with a robust, cloud-based platform to bolster government workforces with world-class skills and qualifications as cyber threats escalate.Jaclyn Sim, Cybersecurity Training Manager for BlackBerry at the Malaysia Cybersecurity Center of Excellence, said, "BlackBerry's partnership with EC-Council represents a meaningful step forward in the shared mission to build a cyber-resilient Malaysia. This initiative builds upon the CCoE's extensive curriculum of online and in-person training, with an advanced, flexible platform that empowers civil servants to learn anytime, anywhere. Together with MCMC, we remain committed to upskilling and fostering a culture of continuous learning across the public sector."Jay Bavisi, Founder and CEO of EC-Council added, "At the heart of this partnership is a shared mission between EC-Council, BlackBerry and the Cybersecurity Center of Excellence to build a cyber-resilient Malaysia by placing trusted, modern cyber learning tools in the hands of every civil servant."Through this initiative, Malaysian civil service professionals will gain access to a full spectrum of programs aligned with national digital ambitions, including:Advanced Cyber Leadership Training: Featuring the globally recognized Certified Chief Information Security Officer (CCISO) program, designed to prepare boardroom-ready executives capable of leading strategic cyber governance and building resilient security operations.Hands-On Technical Skill Development: Delivered through EC-Council's flagship Certified Ethical Hacker (CEH) program and other globally recognized certifications, widely acknowledged as the gold standard in offensive security training.Cyber Essentials for New Entrants: A comprehensive suite of beginner-friendly courses, real-world labs, and interactive Capture-the-Flag (CTF) challenges the largest of its kind globally-designed to onboard new talent into the cybersecurity workforce.This BlackBerry and EC-Council news also coincides with the recent 12-month anniversary of the Cybersecurity Center of Excellence (CCoE), which has rapidly grown into an international hub for cyber talent development, attracting a $3.9M CAD investment from the Government of Canada. Over the past year, the CCoE has launched several initiatives, including multiple partnerships with globally-certified partners such as CompTIA, SANS Institute, ICS2 and Rogers Cybersecure Catalyst, awarded scholarships to aspiring cyber leaders and introduced programs to foster diversity and inclusion in the sector.Find out more about EC-Council courses for Malaysian civil servants at the CCoE via ccoemalaysia@blackberry.com. Visit here for more information about the Malaysia CCoE or follow us on Linkedin.About EC-CouncilThe International Council of E-Commerce Consultants (EC-Council) is a global leader in cybersecurity education, certification, and training. Known for its flagship programs such as Certified Ethical Hacker (CEH) and Certified Chief Information Security Officer (CCISO), EC-Council serves professionals in over 145 countries and is trusted by governments, military agencies, and Fortune 500 companies worldwide.About BlackBerryBlackBerry (NYSE:BB)(TSX:BB) provides enterprises and governments the intelligent software and services that power the world around us. Based in Waterloo, Ontario, the company's high-performance foundational software enables major automakers and industrial giants alike to unlock transformative applications, drive new revenue streams and launch innovative business models, all without sacrificing safety, security, and reliability. With a deep heritage in Secure Communications, BlackBerry delivers operational resiliency with a comprehensive, highly secure, and extensively certified portfolio for mobile fortification, mission-critical communications, and critical events management.For more information, visit BlackBerry.com and follow @BlackBerry.Trademarks, including but not limited to BLACKBERRY and EMBLEM Design, are the trademarks or registered trademarks of BlackBerry Limited, and the exclusive rights to such trademarks are expressly reserved. All other trademarks are the property of their respective owners. BlackBerry is not responsible for any third-party products or services.Media Contacts:BlackBerry Media Relations+1 (519) 597-7273mediarelations@BlackBerry.comMedia Contact - EC-CouncilSean Lim - Senior Vice President (SVP) at EC-Councilsean@eccouncil.orgSOURCE: BlackBerry Copyright 2025 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, July 16, 2025 - (ACN Newswire via SeaPRwire.com) - On the morning of 15 July 2025, China Medical System Holdings Limited (“CMS” or the “Group”) rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8).Nearly one hundred representatives from global professional institutions, shareholders, business partners and employees gathered to witness this strategic moment. Following its successful IPO on the Hong Kong Stock Exchange Main Board in September 2010 , CMS advances with formidable momentum onto the international capital platform, which will attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia to optimize the shareholder structure. This listing also marks a significant milestone for the Group to deepen roots in emerging markets and advance industrial internationalization strategy.At the listing ceremony, Chairman, Chief Executive Officer and President of CMS, Mr. Lam Kong stated: “The secondary listing in Singapore represents a crucial step in implementing CMS’s Asia-Pacific strategy, demonstrating our commitment to extending China’s market advantages across the entire APAC region while strengthening our presence in Southeast Asia and the Middle East. This move not only facilitates CMS’s comprehensive and sustainable development in Asia-Pacific markets, but also enhances our international influence and competitiveness, enabling us to serve broader patient populations with high-quality and affordable medication options.” New CMS New AscentOver the 33-year journey, CMS has continuously challenged and surpassed itself through three strategic transformations to adapt to the external ecosystem: evolving from “China’s largest CSO” (1992-2010), to “transition from CSO to Pharma” (2010-2018), and since 2018, gradually establishing three core strategies of “Innovation-driven, Specialty Breakthroughs and Industrial Internationalization” to promote the upgrading and iteration of “New CMS”, accumulating momentum for takeoff.CMS has established a comprehensive pharmaceutical product lifecycle management system, covering every stage from target identification to clinical development, product registration and commercialization. The Group focuses on FIC (First-in-Class) and BIC (Best-in-Class) innovative products, and has meticulously built a pipeline of approximately 40 innovative products with differentiated advantages, among which 5 innovative drugs have been approved and successfully commercialized in China. With the impact of VBP (Volume-Based Procurement) mostly cleared, CMS has entered a new cycle of high-quality and sustainable development driven by exclusive and innovative drugs.In specialty fields, the Group focuses on cardio-cerebrovascular, gastroenterology, ophthalmology and skin health, continuously deepening product portfolios and expert networks. Notably, the Group’s skin health business “DERMAVON” has emerged as a leader in its sector and is proposed for an independent listing on the Main Board of the Hong Kong Stock Exchange.A Pioneer in Industrial Internationalization Synergized Development Across the Entire “R&D, Manufacturing and Commercialization” Value ChainSince 2022, CMS has initiated its “Industrial Internationalization” strategy by extending the Group’s advantages and resources from the Chinese market to emerging markets. Utilizing Singapore as the strategic pivot, the Group has established a localized cluster comprising CMS R&D, PharmaGend, and Rxilient, achieving synergized development across the entire pharmaceutical value chain from R&D to production and commercialization, driving deeper and broader market expansion across the Asia-Pacific region.Internationalization of the Commercialization System: Rxilient serves as a platform for drug introduction, R&D and commercialization, operated by a professional and experienced localized team. Headquartered in Singapore, its business has expanded to 14 countries and regions including Malaysia, Thailand, Vietnam, the Philippines, Indonesia, and the Middle East, helping partners from China, the US, and Europe bring innovative drugs to emerging markets while introducing more high-quality and affordable treatment options to local markets. As of now, Rxilient has cumulatively submitted marketing applications for nearly 20 drugs and medical devices across Southeast Asia, the Middle East, Hong Kong, Macao and Taiwan, covering therapeutic areas such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system.Internationalization of the Production System: PharmaGend, as an international CDMO platform based in Singapore, has a site spanning 30,000 square meters and is capable of manufacturing dosage forms such as tablets and capsules, with plans to expand production lines for injections, ointments, and nasal sprays. The factory has been certified by international authorities such as the FDA and the HSA, demonstrating its high-standard pharmaceutical manufacturing capabilities for global export .Structural factors including large population bases, healthcare insurance expansion and rising chronic disease burdens are transforming Southeast Asia, the Middle East and other emerging markets into new growth engines for the global pharmaceutical industry. Leveraging its integrated ecosystem, CMS is forming a novel model for Chinese pharmaceutical globalization - not only enabling incremental market conversion for its own products in emerging markets, but also providing global partners with a reliable one-stop solution, thereby generating additional growth momentum for the Group.Looking ahead, CMS will continue advancing its three core strategies to build the long-term value system of “New CMS”. By persistently enhancing accessibility to pharmaceutical innovation, CMS aims to benefit more patients, achieve sustainable healthy development, and deliver substantial value returns to investors.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.

WEST PALM BEACH, FL AND WINDSOR, ENGLAND, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official brand of the United States Polo Association (USPA), in partnership with Brand Machine Group (BMG), its licensing partner in the United Kingdom, proudly served once again as the Official Apparel and Team Sponsor for the 2025 Outsourcing Inc. Royal Charity Polo Cup. The prestigious event took place on July 11 at the renowned Windsor Great Park at Flemish Farms' Guards Polo Club.U.S. Polo Assn.(left to right) U.S. Polo Assn. Team Accepts Royal Charity Polo Cup Trophy: James Beim, HRH The Prince of Wales, J. Michael Prince (USPA Global), Boo Jalil (BMG), Aiyawatt Srivaddhanaprahba, and Amr ZedenIn its seventh consecutive year of sponsorship for the charitable event, U.S. Polo Assn. outfitted all participating polo players, umpires, and flaggers in custom-designed performance jerseys, with The Prince of Wales captaining the U.S. Polo Assn. Team. The annual event brought together elite polo players and distinguished guests for a day of sport and charitable giving.His Royal Highness The Prince of Wales competed in an exciting round-robin format match against Team Fortunis Bloodstock and Team Manta Marine Technologies - La Ilusión Polo Club. The high-profile charitable event featured other well-known polo players, including James Beim, Henry Porter, Jack Richardson, and Ivan Rubinich, to name a few. The match was filled with excellent gameplay from all participants, concluding with The Prince of Wales scoring the game-winning goal against Manta Marine Technologies. The Royal Charity Cup's Most Valuable Player was Emma McCrae from Team Fortunis Bloodstock, who had a great neck-shot goal during the day, alongside the Best Polo Pony, Chechu, played by HRH and owned by King Power Polo.In addition to performance gear, U.S. Polo Assn. provided a limited-edition 135th Anniversary commemorative gift to all event attendees, celebrating the brand's storied heritage dating back to 1890. The tailored gift set included a canvas tote bag, a 135th Anniversary cap, a pocket square, a lapel pin, the brand's newest issue of Field X Fashion magazine, as well as co-branded event caps developed exclusively for this occasion."It is an extraordinary honor to once again have The Prince of Wales lead the U.S. Polo Assn. Team in support of this meaningful charity event," said J. Michael Prince, President and CEO of USPA Global, the company which manages the global, multi-billion-dollar U.S. Polo Assn. brand. "We are proud to stand alongside our partner Brand Machine Group in raising critical funds and awareness through the sport of polo for very important causes that uplift communities across the United Kingdom."The annual high-profile philanthropic event raised more than £1.1 million for 10 important charities that are supported by The Prince and Princess of Wales. The 2025 event contribution takes the total raised from Royal Charity Polo Days played in the U.K. over the last 14 years to more than £14 million.Those charities include: Anna Freud Centre, British Red Cross, Child Bereavement UK, East Anglia's Children's Hospices, Family Action, Fields in Trust, Forward Trust, NHS Charities Together, Royal African Society, and We Are Farming Minds.In addition to U.S. Polo Assn.'s role as the Official Apparel and Team Sponsor, the 2025 Outsourcing Inc. Royal Charity Polo Cup was supported by a distinguished lineup of sponsors, including Lugano Diamonds, AUDI, and Whispering Angel. These prestigious brands joined forces to help elevate the experience for players and guests alike, while reinforcing the event's charitable mission through their shared commitment to excellence, philanthropy, and style."Participating in the 2025 Outsourcing Inc. Royal Charity Polo Cup again is one of the highlights of the British polo season for Brand Machine Group," said Boo Jalil, CEO of Brand Machine Group. "As the U.K. partner of U.S. Polo Assn., we are honored to help further connect the brand with the sport of polo and continue our shared mission of giving back through style and sport."Guards Polo Club is one of only four polo clubs in the United Kingdom that stage elite tournaments, such as the Royal Charity Polo Cup. Founded in 1955 as the Household Brigade Polo Club, with His Royal Highness Prince Philip, Duke of Edinburgh as President, the name was changed to the Guards Polo Club in 1969 and celebrates over six decades of premier polo.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. Historic deals with ESPN in the United States and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, NBA, and MLB, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global and digital growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the USPA and manages the global, multi-billion-dollar U.S. Polo Assn. brand. Through its subsidiary Global Polo Entertainment (GPE), USPA Global also manages Global Polo TV, which provides sports and lifestyle content. For more sports content, visit globalpolo.com.About Brand Machine Group (BMG)BMG is an international leader in fashion innovation, which has established itself as a vertical manufacturer and global licensing specialist with over four decades of industry experience. Partnering with recognized market leaders, BMG manages a seamless and collaborative process of designing, manufacturing, and delivering quality products while championing the DNA of a diverse portfolio of brands, spanning fashion, sports, outdoor, and homeware, including adult fashion, kidswear, and accessories.BMG's portfolio of brands includes U.S. Polo Assn. Penfield, New Balance Kids, Duchamp, Jack Wills, Flyers American Born, Lee Kids, Peckham Rye, Wrangler Kids, Juicy Couture. BMG reaffirms its commitment to upholding sustainable and ethical business practices by ensuring full transparency throughout its global supply chain, aligning with the ETI Base Code.Visit brandmachinegroup.com and follow @brandmachinegroup. For appointments, contact sales@brandmachinegroup.com.Photo Captions:1. (left to right) U.S. Polo Assn. Team Accepts Royal Charity Polo Cup Trophy: James Beim, HRH The Prince of Wales, J. Michael Prince (USPA Global), Boo Jalil (BMG), Aiyawatt Srivaddhanaprahba, and Amr Zeden2. HRH The Prince of Wales and Aiyawatt Srivaddhanaprahba Competing in the 2025 Outsourcing Inc. Royal Charity Polo Cup at Windsor Great Park at Flemish Farms' Guards Polo ClubPhoto Credit: Chris Jackson/Getty Images for Outsourcing Inc. Royal Charity Polo CupContact InformationShannon StilsonVP, Sports Marketing and Mediasstilson@uspagl.com+001.561.227.6994Gina DigregorioHead of Marketinggina.digregorio@brandmachinegroup.com+44 (0) 7741 635 984Stacey KovalskyVP, Global PR & Communicationsskovalsky@uspagl.com+001.561.790.8036SOURCE: U.S. Polo Assn.Related ImagesU.S. Polo Assn.HRH The Prince of Wales and Aiyawatt Srivaddhanaprahba Competing in the 2025 Outsourcing Inc. Royal Charity Polo Cup at Windsor Great Park at Flemish Farms’ Guards Polo Club Copyright 2025 ACN Newswire via SeaPRwire.com.

ROMEOVILLE, IL, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, today announced an agreement with GEON® Performance Solutions that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in North America and South America.The agreement follows GEON's acquisition of Foster, LLC, and builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials."This expanded partnership equips our customers with a broader set of proven medical-grade solutions while leveraging Formerra's technical guidance and robust supply-chain capabilities," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Foster's brand strength and GEON's investment momentum create powerful growth potential for these materials and our customers."Foster, LLC brings more than 30 years of expertise in custom medical polymer compounding, offering highly engineered formulations. Ranging from radio-opaque and pre-colored to USP Class VI and ISO 10993-compliant grades, Foster materials serve critical applications such as medical device housings, drug-delivery and auto-injector components, surgical tools, and remote patient monitoring devices."It is a privilege to serve the high-growth healthcare and medical device industry as GEON embarks on this new journey with Foster and Formerra," said Arthur Adams, Chief Commercial Officer, GEON. "Our partnership with Formerra will expand our global footprint and enable us to distribute medical-grade engineered polymers to even more customers."With the addition of Foster, LLC compounds to its portfolio, Formerra further deepens its leading position in the healthcare space by delivering unmatched access to engineered medical polymers, deep regulatory expertise, and responsive logistics across the Americas.Key details--Formerra will distribute Foster®, LLC medical compounds in North and South America.--This agreement adds custom medical-grade compounds to Formerra's existing global access to GEON® PVC and filled PP materials.--Foster®, LLC material applications include medical device housings, drug-delivery and auto-injectors, surgical tools, remote patient monitoring components, and more.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About GEONGEON® Performance Solutions is a global leader in the formulation, development and manufacture of performance polymer solutions. With a portfolio of highly adaptable vinyl and polyolefin polymer technologies as well as a full-service manufacturing business, GEON combines three powerful traditions into a single, customer-focused business. GEON Performance Solutions is a leading innovator in the development of performance material solutions for a broad range of markets including appliances, building & infrastructure, electronics, medical, transportation, power & communications and more. GEON Performance Solutions has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Please visit us at www.geon.com to learn more. GEON Performance Solutions is a portfolio company of SK Capital Partners.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.comSOURCE: Formerra Copyright 2025 ACN Newswire via SeaPRwire.com.

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsinLead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of actionVILNIUS, Lithuania, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).AATec Medical and Northway Biotech Announce PartnershipUnder the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system."With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis.""We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step.""We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area."AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties.About AATec MedicalAG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit https://www.aatec-medical.com/ and follow AATec on LinkedIn.About Northway BiotechNorthway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit https://www.northwaybiotech.com.Northway Biotech Contact:Prof. Vladas Algirdas BumelisCEO and Chairman of the Boardvladas.bumelis@northwaybiotech.comAATec Medical Contact:Dr. Rüdiger Jankowsky, CEOinfo@aatec-medical.comMedia Contact:MC ServicesKatja Arnold, Julia von Hummelaatec-medical@mc-services.euPhone: +49 (0)89 2102280SOURCE: Northway Biotech Copyright 2025 ACN Newswire via SeaPRwire.com.

双方建立合作关系，以开发并扩大 ATL-105 的生产规模。ATL-105 是一种新型重组 α1-抗胰蛋白酶。主要适应症为非囊性纤维化支气管扩张症；ATL-105 通过广泛的多模式作用机制，靶向疾病驱动因素。立陶宛维尔纽斯, 2025年7月16日 - (亚太商讯 via SeaPRwire.com) - AATec Medical GmbH（简称“AATec”）是一家致力于开发用于治疗呼吸系统疾病的多产品平台的生物技术公司。 Northway Biotech（简称“Northway Biotech”或“NBT”）是一家全球合同开发与制造组织（CDMO）。两家公司今日宣布建立合作关系，联合开展 AATec 旗下主要候选产品 ATL-105 的生产工艺开发与分析方法开发。ATL-105 是一种专有的重组 α1-抗胰蛋白酶（AAT）吸入式疗法，适用于治疗非囊性纤维化支气管扩张症（NCFB）。AATec Medical 与 Northway Biotech 宣布合作根据协议，Northway Biotech 将利用其在生物制剂生产方面的专业知识，采用毕赤酵母（Pichia pastoris）表达系统开发并扩大 ATL-105 的生产工艺。AATec 联合创始人兼首席执行官、博士 Rüdiger Jankowsky 表示：“通过此次合作，我们正在建立一套稳健且可扩展的 ATL-105 生产工艺，为临床开发和商业化应用奠定一致的质量基础。”他补充道：“ATL-105 代表新一代吸入式生物制剂，在单一分子中结合抗蛋白酶、抗炎和抗感染特性。通过直接递送至肺部，实现快速、精准的作用，并最大程度减少全身暴露。我们相信，ATL-105 有望重新定义如非囊性纤维化支气管扩张症等高未满足医疗需求呼吸疾病的治疗方式。”Northway Biotech 首席执行官兼董事长 Vladas Algirdas Bumelis 教授表示：“我们非常高兴能支持 AATec 向临床试验迈进。AATec 正在推进一项极具前景的治疗方案，旨在应对显著的未满足医疗需求，并拥有一支高效且敬业的团队。凭借我们在微生物系统方面数十年的专业经验，我们有能力高效扩大该项目的生产规模，并在每一个环节确保质量。”Northway Biotech 商务拓展副总裁、博士 André Markmann 补充道：“我们意识到这是一个有潜力显著改善呼吸系统疾病患者护理方式的项目，并希望为其提供支持。吸入式蛋白质疗法正日益受到关注，而 ATL-105 是该领域最具前景的方法之一。”AATec 正在开发 ATL-105，用于治疗非囊性纤维化支气管扩张症（NCFB）——这是一种慢性炎症性呼吸系统疾病，影响着全球数百万患者。该疾病表现为支气管扩张、持续性炎症、频繁的气道感染以及黏液清除功能受损。除了 NCFB 之外，ATL-105 还具有治疗更广泛炎症性和感染性呼吸系统疾病的潜力，例如慢性阻塞性肺疾病（COPD）、急性呼吸窘迫综合征（ARDS）以及其他适应症，充分体现了其抗炎、免疫调节和抗感染的多重作用机制与广泛适用性。关于 AATec MedicalAATec Medical GmbH 是一家生物技术公司，致力于开发以新型重组 α1-抗胰蛋白酶（AAT）为基础的产品平台，用于治疗呼吸道炎症性疾病、气道感染以及罕见病。公司已在多个适应症中成功验证其概念可行性，目前正在为首个候选产品 ATL-105（用于吸入式治疗非囊性纤维化支气管扩张症）开展概念验证临床试验做准备。AATec 由一支在临床研究、生物制药开发和产品产业化方面具有丰富经验的跨学科团队创立。欲了解更多信息，请访问： https://www.aatec-medical.com/ 并关注 AATec 的 LinkedIn页面。关于 Northway BiotechNorthway Biotech 是一家领先的合同开发与制造组织（CDMO），专注于蛋白质类生物制剂和基因疗法，提供全面的一站式生物制药开发与生产服务。公司在细胞株开发、工艺优化以及 cGMP 生产方面拥有深厚专业知识，支持从早期开发到商业化生产的各阶段项目。Northway Biotech 成立于 2004 年，是一家私人控股企业，在立陶宛和美国设有先进的生产设施，能够根据客户的独特需求提供高质量、合规的解决方案。欲了解更多信息，请访问：https://www.northwaybiotech.com 。Northway Biotech 媒体联系:Prof. Vladas Algirdas BumelisCEO and Chairman of the Boardvladas.bumelis@northwaybiotech.comAATec Medical 媒体联系:Dr. Rüdiger Jankowsky, CEOinfo@aatec-medical.com媒体联系:MC ServicesKatja Arnold, Julia von Hummelaatec-medical@mc-services.euPhone: +49 (0)89 2102280来源: Northway Biotech Copyright 2025 亚太商讯 via SeaPRwire.com.

深圳，2025年7月15日 - (亚太商讯 via SeaPRwire.com) - 7月15日上午，康哲药业控股有限公司（"康哲药业"或"集团"）在新加坡交易所正式鸣锣上市（证券简称：CMS，股票代码：8A8）。近百名全球专业机构代表、股东代表、合作伙伴代表以及员工代表，共同见证这一具有战略意义的时刻。这是康哲药业继2010年9月成功登陆香港联交所主板之后，再度以磅礴之势迈向国际资本平台，将吸引专注亚太投资的基金及东南亚本土资本，优化股东结构。同时，也标志着集团深耕新兴市场、推进产业国际化战略的重要里程碑。康哲药业主席兼行政总裁、总裁林刚先生在上市仪式现场致辞："在新加坡的二次上市，标志着康哲药业实施亚太战略迈出了关键一步，彰显了我们将中国市场优势延伸至整个亚太地区、深化东南亚及中东布局的决心。这不仅助力康哲药业在亚太市场全方位、可持续发展，更提升了公司的国际影响力与竞争力，使我们能够覆盖更广泛的患者群体，为他们提供优质、可负担的用药选择。"新康哲 新崛起三十三年征程，康哲药业通过三次战略转型不断挑战与超越以适配外部生态：从"中国最大CSO"（1992-2010年），到"从CSO向Pharma转换"（2010年起-2018年），再到自2018年起，逐步确立"创新驱动、专科突破、产业国际化"三大核心战略，推动"新康哲"升级迭代，蓄势而发。康哲药业已建立医药产品全生命周期管理体系，覆盖从靶点识别到临床开发，再到产品注册及商业化推广的每一个环节。集团专注FIC、BIC创新产品，精心打造了约 40 款具有差异化优势的创新产品管线，其中 5 款创新药已在中国获批并成功商业化。随着集采影响基本出清，康哲药业已进入由独家药、创新药驱动的高质量、可持续发展新周期。专科方面，集团聚焦心脑血管、消化、眼科、皮肤健康等领域，持续深化产品布局与专家网络。值得一提的是，集团皮肤健康业务"德镁医药"，已在细分领域崭露头角，成为行业领军者，并计划于香港联交所主板独立上市。产业国际化出海先锋"研、产、销"全链条协同发力自2022年起，康哲药业启动"产业国际化"战略，将集团在中国市场的优势与资源外溢至新兴市场，并以新加坡为支点，建立涵盖CMS R&D、PharmaGend以及Rxilient在内的本地化集群，实现医药产业"研、产、销"全链条协同发力，放眼全亚太拓展市场深度与广度。商业化体系国际化：Rxilient为药品引进、开发、营销推广平台，由专业、经验丰富的本土化团队运营，以新加坡为总部，业务已拓展至马来西亚、泰国、越南、菲律宾、印尼、中东等14个国家和地区，助力中、美、欧等地合作伙伴的创新药落地新兴市场，同时为当地引入更多优质、可负担的治疗选择。截至目前，Rxilient在东南亚、中东、港澳台地区累计提交了近20款药品和医疗器械的上市申请，覆盖皮肤科、眼科、肿瘤、自身免疫、中枢神经等疾病领域。生产体系国际化：PharmaGend作为国际化CDMO平台，以新加坡为基地，拥有3万平方米生产场地，可生产片剂、胶囊等剂型，并规划拓展注射剂、软膏剂、鼻喷剂等产线，工厂已通过FDA、HSA等国际认证，具备面向全球输出的高标准药品制造能力。庞大人口基数、医保扩容与慢病负担上升等结构性因素，正推动东南亚、中东等新兴市场成为全球医药产业新增长极。康哲药业依托全链条生态体系，正逐步形成中国医药产业出海的新模式，不仅赋能自身产品的新兴市场增量转化，也为全球合作伙伴提供可信的一站式落地机制，为集团注入额外的增长动能。展望未来，康哲药业将持续推动三大核心战略以构建"新康哲"长期价值体系，不断提升医药创新可及性，助力更多患者获益，实现可持续健康发展，并为投资者创造丰厚价值回报。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com.